Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study

BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer with increasing incidence and mortality worldwide. For metastatic disease, systemic treatment is recommended. In addition to tumor characteristics, adverse events (AEs) may influence regimen choice. AIM: To analyze heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lal, Lincy S., Aly, Abdalla, Le, Lisa B., Peckous, Susan, Seal, Brian, Teitelbaum, April
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124510/
https://www.ncbi.nlm.nih.gov/pubmed/34494389
http://dx.doi.org/10.1002/cnr2.1504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124510/
https://www.ncbi.nlm.nih.gov/pubmed/34494389
http://dx.doi.org/10.1002/cnr2.1504

Ejemplares similares